Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AFDX 0250BS

Next Previous
X
Search
Drug Profile

AFDX 0250BS

Alternative Names: AFDX-0250BS; STN-1013400

Latest Information Update: 23 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Santen Pharmaceutical
  • Developer Boehringer Ingelheim; Santen Pharmaceutical
  • Class Eye disorder therapies
  • Mechanism of Action Muscarinic M2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Myopia

Most Recent Events

  • 31 Aug 2023 Phase-I clinical trials in Myopia in China (unspecified route) before November 2023 (Santen Pharmaceutical pipeline, November 2023)
  • 31 May 2023 Phase-II clinical trials in Myopia in Japan (unspecified route) (Santen Pharmaceutical pipeline, July 2023)
  • 31 Jul 2021 Phase-I clinical trials in Myopia in Japan (unspecified route) in July 2021 (Santen Pharmaceuticals pipeline, August 2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top